Accuray Incorporated has announced that the CyberKnife® Center Salzburg is the first medical facility in Austria to begin treating patients using the CyberKnife® System, marking a significant advancement in the country's radiation oncology capabilities. The center commissioned the latest-generation CyberKnife S7™ System using Accuray’s CyberComm™ technology, enabling an efficient start to patient treatments. This milestone expands access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), techniques known for delivering precise, high-dose radiation treatments in significantly fewer sessions than traditional radiotherapy.

The CyberKnife System is uniquely suited for ultra-hypofractionated treatment, delivering sub-millimeter precision and allowing most treatment plans to be completed in just one to five outpatient sessions. This approach offers considerable benefits to patients who would otherwise face lengthy, daily treatments over several weeks. The growing body of clinical evidence supports ultra-hypofractionation for many indications, showing it can match or even improve outcomes compared to conventional treatment while reducing healthcare costs. The adoption of the CyberKnife System reflects a broader shift in cancer care towards more efficient, patient-centric therapies.

Austria faces a projected 25% increase in cancer cases by 2040, yet its radiotherapy infrastructure remains under-resourced compared to EU averages. The introduction of the CyberKnife System in Salzburg helps address this gap, providing advanced treatment options to more patients. Dr. Alfred Haidenberger, a radiation oncologist and lead at the CyberKnife® Center Salzburg, emphasized the system’s impact on patient quality of life by enabling faster, more tolerable treatment regimens. Accuray’s collaboration with the center exemplifies its commitment to improving global access to precise and innovative cancer care solutions.